Home › Amarantus Receives Orphan Drug Designation For Eltoprazine
 

Keywords :   


Amarantus Receives Orphan Drug Designation For Eltoprazine

2016-02-11 06:24:55| drugdiscoveryonline News Articles

Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

Tags: drug receives designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.12South Western Railway to be renationalised by Labour
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
03.12WEG Achieves Gold Certification in EcoVadis for Second Consecutive Year
More »